SUDEEPPHRM Q4 FY26 Guidance vs Delivery (SUDEEPPHRM Management Mirror)

Revenue and Growth Outlook

Management expects the Pharma, Food, and Nutrition segment to accelerate beyond FY26's 10% growth rate in FY27, while the core business holds potential to scale to INR 1,000 to 1,200 crores without additional capex following the greenfield facility commissioning. In the Sep'25 Qtr, management projected sustaining a 26% growth rate for the remainder of FY26, before broadening the outlook in the Dec'25 Qtr to anticipate sustained historical growth driven by export markets and the Specialty Ingredients segment, which remains the fastest-growing vertical into the Mar'26 Qtr. [Status: Reaffirmed]